275 related articles for article (PubMed ID: 26038471)
21. Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.
Gopal P; Yee M; Sarathy J; Low JL; Sarathy JP; Kaya F; Dartois V; Gengenbacher M; Dick T
ACS Infect Dis; 2016 Sep; 2(9):616-626. PubMed ID: 27759369
[TBL] [Abstract][Full Text] [Related]
22. Identification of Novel Efflux Proteins Rv0191, Rv3756c, Rv3008, and Rv1667c Involved in Pyrazinamide Resistance in Mycobacterium tuberculosis.
Zhang Y; Zhang J; Cui P; Zhang Y; Zhang W
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584158
[TBL] [Abstract][Full Text] [Related]
23. Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD.
Gopal P; Nartey W; Ragunathan P; Sarathy J; Kaya F; Yee M; Setzer C; Manimekalai MSS; Dartois V; Grüber G; Dick T
ACS Infect Dis; 2017 Nov; 3(11):807-819. PubMed ID: 28991455
[TBL] [Abstract][Full Text] [Related]
24. Exploring the Pyrazinamide Drug Resistance Mechanism of Clinical Mutants T370P and W403G in Ribosomal Protein S1 of Mycobacterium tuberculosis.
Rehman AU; Khan MT; Liu H; Wadood A; Malik SI; Chen HF
J Chem Inf Model; 2019 Apr; 59(4):1584-1597. PubMed ID: 30810312
[TBL] [Abstract][Full Text] [Related]
25. [Characteristics of pncA gene in multidrug-resistant Mycobacterium tuberculosis isolates and its correlation with drug resistance to pyrazinamide].
Hong CY; Wang F; Gui J; Liu XL
Zhonghua Yu Fang Yi Xue Za Zhi; 2012 May; 46(5):436-9. PubMed ID: 22883731
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China.
Xia Q; Zhao LL; Li F; Fan YM; Chen YY; Wu BB; Liu ZW; Pan AZ; Zhu M
Antimicrob Agents Chemother; 2015 Mar; 59(3):1690-5. PubMed ID: 25583712
[TBL] [Abstract][Full Text] [Related]
27. Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis: A Review and Update.
Rajendran A; Palaniyandi K
Curr Microbiol; 2022 Oct; 79(11):348. PubMed ID: 36209317
[TBL] [Abstract][Full Text] [Related]
28. Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates.
Mok S; Roycroft E; Flanagan PR; Montgomery L; Borroni E; Rogers TR; Fitzgibbon MM
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0261720. PubMed ID: 33972244
[TBL] [Abstract][Full Text] [Related]
29. Insights into the Mechanisms of the Pyrazinamide Resistance of Three Pyrazinamidase Mutants N11K, P69T, and D126N.
Junaid M; Khan MT; Malik SI; Wei DQ
J Chem Inf Model; 2019 Jan; 59(1):498-508. PubMed ID: 30481017
[TBL] [Abstract][Full Text] [Related]
30. Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide.
Yang J; Liu Y; Bi J; Cai Q; Liao X; Li W; Guo C; Zhang Q; Lin T; Zhao Y; Wang H; Liu J; Zhang X; Lin D
Mol Microbiol; 2015 Mar; 95(5):791-803. PubMed ID: 25430994
[TBL] [Abstract][Full Text] [Related]
31. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide.
Sun Z; Zhang Y
Antimicrob Agents Chemother; 1999 Mar; 43(3):537-42. PubMed ID: 10049264
[TBL] [Abstract][Full Text] [Related]
32. Insights Into Mutations Induced Conformational Changes and Rearrangement of Fe
Nangraj AS; Khan A; Umbreen S; Sahar S; Arshad M; Younas S; Ahmad S; Ali S; Ali SS; Ali L; Wei DQ
Front Mol Biosci; 2021; 8():633365. PubMed ID: 34095218
[TBL] [Abstract][Full Text] [Related]
33. Insight into novel clinical mutants of RpsA-S324F, E325K, and G341R of
Khan MT; Rehaman AU; Junaid M; Malik SI; Wei DQ
Comput Struct Biotechnol J; 2018; 16():379-387. PubMed ID: 30402208
[TBL] [Abstract][Full Text] [Related]
34. The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide.
Daneau G; Gumusboga M; De Rijk P; Trebucq A; Rigouts L; Van Deun A; de Jong BC
Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S46-S47. PubMed ID: 28043604
[TBL] [Abstract][Full Text] [Related]
35. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing.
Shenai S; Rodrigues C; Sadani M; Sukhadia N; Mehta A
Indian J Tuberc; 2009 Apr; 56(2):82-90. PubMed ID: 19810590
[TBL] [Abstract][Full Text] [Related]
36. Molecular principles behind pyrazinamide resistance due to mutations in panD gene in Mycobacterium tuberculosis.
Pandey B; Grover S; Tyagi C; Goyal S; Jamal S; Singh A; Kaur J; Grover A
Gene; 2016 Apr; 581(1):31-42. PubMed ID: 26784657
[TBL] [Abstract][Full Text] [Related]
37. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea.
Lee KW; Lee JM; Jung KS
J Korean Med Sci; 2001 Oct; 16(5):537-43. PubMed ID: 11641519
[TBL] [Abstract][Full Text] [Related]
38. A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis.
Ramirez-Busby SM; Rodwell TC; Fink L; Catanzaro D; Jackson RL; Pettigrove M; Catanzaro A; Valafar F
Sci Rep; 2017 Jun; 7(1):3790. PubMed ID: 28630430
[TBL] [Abstract][Full Text] [Related]
39. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.
Shi W; Zhang X; Jiang X; Yuan H; Lee JS; Barry CE; Wang H; Zhang W; Zhang Y
Science; 2011 Sep; 333(6049):1630-2. PubMed ID: 21835980
[TBL] [Abstract][Full Text] [Related]
40. Characterization of
Li K; Yang Z; Gu J; Luo M; Deng J; Chen Y
Front Microbiol; 2020; 11():594171. PubMed ID: 33505367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
